Cargando…

Spinal Muscular Atrophy: The Treatment Approved

Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder resulting in progressive muscle weakness and atrophy. It is universally fatal, especially if the respiratory muscles are involved leading to repetitive aspiration and respiratory failure. Historically, the treatment for this dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabet, Rabih, El Bitar, Sandy, Zaidan, Julie, Dabaghian, Garbis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669527/ https://www.ncbi.nlm.nih.gov/pubmed/29142792 http://dx.doi.org/10.7759/cureus.1644

Ejemplares similares

Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy
por: Millere, Elina, et al.
Publicado: (2021)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
por: Savini, Giovanni, et al.
Publicado: (2021)

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
por: Kariyawasam, Didu S. T., et al.
Publicado: (2019)

Expression of Human Endogenous Retrovirus-K in Spinal and Bulbar Muscular Atrophy
por: Rex, Cody, et al.
Publicado: (2019)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era
por: Giorgia, Querin, et al.
Publicado: (2023)

Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
por: Yeo, Crystal J. J., et al.
Publicado: (2022)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment
por: Nigro, Elisa, et al.
Publicado: (2023)

Correlation Between Maximal Tongue Pressure and Swallowing Function in Spinal and Bulbar Muscular Atrophy
por: Gwak, Dae-Won, et al.
Publicado: (2021)

Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
por: Kotulska, Katarzyna, et al.
Publicado: (2021)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Real-World Data on Access to Standards of Care for People With Spinal Muscular Atrophy in the UK
por: Muni-Lofra, Robert, et al.
Publicado: (2022)

Sociodemographic and clinical characteristics and access to health care in patients with spinal muscular atrophy in Argentina
por: Vazquez, Gabriel Adolfo, et al.
Publicado: (2023)

Cognitive impairment in Chinese adult patients with type III spinal muscular atrophy without disease-modifying treatment
por: Hu, Ying, et al.
Publicado: (2023)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Spinal Muscular Atrophy and Communicating Hydrocephalus: A Novel or a Well-Established Rare Association?
por: Alkhars, Fatimah Z, et al.
Publicado: (2020)

Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs
por: Leon-Astudillo, Carmen, et al.
Publicado: (2022)

Lowered oxidative capacity in spinal muscular atrophy, Jokela type; comparison with mitochondrial muscle disease
por: Ratia, Nadja, et al.
Publicado: (2023)

Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment—A Pilot Study
por: Thimm, Andreas, et al.
Publicado: (2022)

Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives
por: Farrar, Michelle A, et al.
Publicado: (2018)

Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis
por: Darbà, Josep, et al.
Publicado: (2019)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen
por: Yae, Yukako, et al.
Publicado: (2022)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy
por: Ottesen, Eric W.
Publicado: (2017)

Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine
por: Chaytow, Helena, et al.
Publicado: (2021)

A New Method for Measuring Bell-Shaped Chest Induced by Impaired Ribcage Muscles in Spinal Muscular Atrophy Children
por: LoMauro, Antonella, et al.
Publicado: (2018)

Intrathecal Access Through Suboccipital Port in Patients With Spinal Muscular Atrophy and Complex Spines: Case Series and Technical Note
por: Tran, Diem Kieu, et al.
Publicado: (2020)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2019)

Neck and Trunk Muscle Strength in Children With Spinal Muscular Atrophy Is Lower Than in Healthy Controls and Depends on Disease Type
por: Stępień, Agnieszka, et al.
Publicado: (2021)

A comparative analysis of body composition assessment by BIA and DXA in children with type II and III spinal muscular atrophy
por: Wang, Wenqiao, et al.
Publicado: (2022)

Comprehensive profile and natural history of pediatric patients with spinal muscular atrophy: A large retrospective study from China
por: Hu, Chaoping, et al.
Publicado: (2022)

Homozygous TRPV4 Mutation Broadens the Phenotypic Spectrum of Congenital Spinal Muscular Atrophy and Arthrogryposis: A Case Report
por: Lugo, Elyette, et al.
Publicado: (2023)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy
por: Chen, Tai-Heng
Publicado: (2020)

Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy
por: Günther, René, et al.
Publicado: (2019)

Spinal muscular atrophy type I associated with a novel SMN1 splicing variant that disrupts the expression of the functional transcript
por: Votsi, Christina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_474t73o3k6mar30hts8nkuk9ff